| Reconciliation Of Operating Profit Loss From Segments To Consolidated |
For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
(in thousands) |
|
|
(in thousands) |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Manufacturing of preclinical and clinical supplies |
|
$ |
13,855 |
|
|
$ |
11,610 |
|
|
$ |
24,647 |
|
|
$ |
16,642 |
|
Personnel |
|
|
12,809 |
|
|
|
12,001 |
|
|
|
25,199 |
|
|
|
23,366 |
|
Clinical trials |
|
|
11,430 |
|
|
|
9,070 |
|
|
|
22,434 |
|
|
|
17,581 |
|
License of intellectual property |
|
|
3,000 |
|
|
|
— |
|
|
|
3,000 |
|
|
|
— |
|
Development services |
|
|
2,178 |
|
|
|
4,197 |
|
|
|
4,534 |
|
|
|
7,765 |
|
Other research and development costs (1) |
|
|
1,158 |
|
|
|
760 |
|
|
|
1,969 |
|
|
|
1,302 |
|
General and administration expenses |
|
|
7,591 |
|
|
|
8,268 |
|
|
|
14,534 |
|
|
|
16,386 |
|
Interest income |
|
|
(1,604 |
) |
|
|
(1,410 |
) |
|
|
(2,680 |
) |
|
|
(2,897 |
) |
Interest expense |
|
|
517 |
|
|
|
571 |
|
|
|
1,153 |
|
|
|
865 |
|
Other (income) expense, net |
|
|
84 |
|
|
|
61 |
|
|
|
(257 |
) |
|
|
61 |
|
Net loss |
|
$ |
51,018 |
|
|
$ |
45,128 |
|
|
$ |
94,533 |
|
|
$ |
81,071 |
|
(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.
|